pharmaphorum December 6, 2023
Phil Taylor

Novartis’ targeted factor B inhibitor iptacopan has become the first oral monotherapy to be approved by the FDA for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH).

The drug, which will be sold as Fabhalta, offers an alternative to therapies for PNH like AstraZeneca/Alexion’s complement C5 inhibitors Soliris (eculizumab) and Ultomiris (ravulizumab) and Apellis’ C3 inhibitor Empaveli (pegcetacoplan) that need to be delivered either by infusion or injection. It has been approved with a broad label, covering previously treated and treatment-naïve patients.

Victor Bultó, president of Novartis in the US, said that the approval of Fabhalta “may mean that patients can reset their expectations of living with PNH.”

Analysts at Jefferies have previously said that iptacopan could hit $3.6 billion in...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients
Latigo raises $150M to get non-opioid pain drugs through key tests
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
CMS doubles down on Medicare drug price negotiations
Drug shortages could surge 25% as AI reshapes specialty pharmacy: Survey

Share This Article